PMOS vs PCOS

If you searched "PMOS vs PCOS" you probably want to know whether you have something new, whether your diagnosis still applies, and whether your treatment needs to change. The short answer is no, no, and no. This post walks through what stayed the same, what shifted, and what the rename means for symptoms, diagnosis, and care.

For context on the rename itself (who made it, when, and why), see PCOS renamed to PMOS.

The one thing to know

PMOS and PCOS describe the same condition. A May 2026 paper in The Lancet, led by Helena Teede of Monash University, renamed PCOS (polycystic ovary syndrome) to PMOS (polyendocrine metabolic ovarian syndrome) through a multistep global consensus.

If you have a PCOS diagnosis, you have a PMOS diagnosis. Same chart, same labs, same plan.

What stayed the same

The diagnostic criteria

The Rotterdam criteria, published in 2003 and reaffirmed in the 2023 international evidence-based guideline, remain the standard. Diagnosis requires at least two of three features:

1. Ovulatory dysfunction. Irregular cycles (typically longer than 35 days or fewer than 8 cycles per year) or absent ovulation.
2. Androgen excess. Either clinical signs (acne, hirsutism, scalp hair thinning) or elevated biochemical androgens on blood work.
3. Polycystic ovarian morphology. 12 or more follicles per ovary on ultrasound, OR elevated anti-Mullerian hormone (AMH), in line with current age-adjusted thresholds.

Other potential causes (thyroid dysfunction, hyperprolactinemia, non-classical congenital adrenal hyperplasia, Cushing syndrome) must be ruled out first.

The symptoms

Symptoms of PMOS are the same symptoms previously associated with PCOS. The presentation varies significantly between individuals, but the most common features are:

• Menstrual irregularity. Cycles longer than 35 days, fewer than 8 per year, or absent altogether (amenorrhea). Some women bleed unpredictably; others go months between periods.
• Hyperandrogenism. Acne (especially along the jawline and chin), hirsutism (excess hair on face, chin, chest, lower abdomen), and scalp hair thinning at the crown or temples.
• Insulin resistance. Present in roughly 70 percent of women with PMOS regardless of weight. Fasting insulin, HOMA-IR, or a 2-hour glucose tolerance test reveals it. Insulin resistance is the metabolic driver behind much of the rest.
• Weight regulation difficulty. Particularly around the midsection. This is driven by insulin resistance and androgen excess, not by behavior alone.
• Fertility challenges. Anovulatory infertility is the most common medical reason for difficulty conceiving in women with PMOS.
• Mood and sleep. Higher rates of depression, anxiety, and sleep apnea than the general population.

The treatments

Management of PMOS uses the same toolkit as PCOS management. The 2023 international evidence-based guideline (still active under the new name) sets first-line recommendations:

• Lifestyle interventions for weight, metabolism, and cycle regularity. Diet quality, strength training, and sleep are first-line for most women.
• Combined hormonal contraception for cycle regulation and androgen suppression in women not trying to conceive.
• Metformin when insulin resistance is documented and lifestyle alone is insufficient. Newer options include GLP-1 agonists for selected patients with significant metabolic features.
• Letrozole for ovulation induction when fertility is the goal.
• Anti-androgens (spironolactone, finasteride) for hirsutism and acne in selected patients.
• Topical and procedural treatments for skin and hair manifestations.

None of these changed. Brand names and doses are not affected by the rename.

What shifted

The framing of the condition

This is the part the renaming committee cared about. The old name implied that the problem was cysts on the ovaries. It is not. The visible structures on ultrasound are arrested follicles, not cysts. The condition is fundamentally an endocrine and metabolic disorder that happens to manifest in the ovaries.

The new name puts the metabolic and endocrine nature first. This matters because:

• Care is more likely to be integrated. Endocrinologists and gynecologists now share an obvious common frame rather than each treating their corner.
• Metabolic screening is more likely to happen. Insulin testing, lipid panels, and cardiovascular risk assessment become harder to skip when the name itself signals their relevance.
• Diagnosis happens earlier. Women presenting with metabolic symptoms (insulin resistance, weight regulation issues) and irregular cycles get pattern-matched to PMOS faster than they did to PCOS, where the cyst framing pushed the diagnostic frame toward ultrasound first.

What patient advocacy emphasizes

Patient organizations have lobbied for a name change for years. The Stein-Leventhal name (the original eponym) and the polycystic name both centered descriptive features and dropped what felt important. Advocacy groups argued that:

• The "polycystic" framing made many women feel something was wrong with their ovaries that needed surgical attention.
• The cyst framing made the metabolic burden invisible to patients.
• The old name was a barrier to discussing the condition openly, both clinically and personally.

With PMOS, the framing pushes the conversation toward systemic risk management and away from the misleading focus on ovarian structure.

The cycle syncing relevance

If you have PMOS and have tried cycle syncing protocols designed around a 28-day cycle, you may have noticed the standard model does not fit. That is not your fault and it is not because cycle syncing does not work for you. The four-phase model assumes regular ovulation. When ovulation is inconsistent, the phase rhythm does not happen the same way.

A more useful approach for women with PMOS:

1. Track symptoms, not days. Energy, mood, sleep, appetite, skin, and blood glucose response to meals are more informative than guessing what day of a phase you might be in.
2. Pay attention to insulin patterns. Postprandial glucose response and how you feel 2 to 3 hours after meals signal whether your current diet is helping or hurting.
3. Use medical management to your advantage. If your provider has you on letrozole, metformin, or hormonal contraception, your "cycle" pattern is partially set by those medications, which changes what cycle syncing means in practice.
4. Skip the food charts. Phase-specific food prescriptions are not evidence-based even for women without PMOS. They are doubly inappropriate for women whose cycles are not regular.

For the general case, see does cycle syncing work for the evidence-graded answer and is cycle syncing legit for where the science stops and the marketing begins.

How long will the transition take

The rename will roll out in layers. If you are reading this in mid-2026:

• Medical literature: already using PMOS in new papers as of May 2026.
• Patient-facing organizations: rebranding over the next 3 to 9 months. Expect PCOS Challenge, Verity, and AskPCOS to update.
• Electronic health records: 6 to 18 months. EHR vendors move slowly.
• Insurance and billing: tied to ICD coding updates, which are scheduled annually. Expect a transition window where both terms map to the same codes.
• Mainstream patient materials: 1 to 2 years before PMOS is the default in popular articles.

Search engines will treat both terms as related during the transition. If you are researching a topic, search both for completeness.

What to ask your doctor

Most patients do not need a separate appointment to discuss the name change. At your next regular visit, useful questions include:

1. "Is my current care plan covering both the reproductive and the metabolic dimensions?" The new name's central point is integrated care; this is the prompt that turns the rename into a clinical conversation.
2. "When was my last insulin or fasting glucose test?" Many women with PCOS were managed for cycle and skin issues without ongoing metabolic surveillance. PMOS framing makes that gap visible.
3. "Should anything in my management change in light of the rename?" Almost always the answer is no. But asking the question puts your provider on notice that you are tracking the evolution of the condition.
4. "What is my cardiovascular risk profile?" Long-term cardiovascular risk is elevated in PMOS, and screening tends to be under-prioritized in younger women whose primary concern is cycles or fertility.

Bottom line

PMOS is PCOS, renamed. If you had PCOS yesterday, you have PMOS today. The criteria, symptoms, and treatments did not change. What changed is the framing, from "cysts on the ovaries" to "multi-system endocrine and metabolic condition", and the integration that the new name pushes for. Over the next year, expect both names to appear interchangeably; over the next 5 years, expect PMOS to become the default.

The most useful thing the rename gives you, if you have the condition, is permission to ask whether your care has been treating the right problem.

For a focused look at the announcement itself, see PCOS renamed to PMOS.